Last updated: April 30, 2026
What does BR112013032610 claim, and how does it sit in Brazil’s patent landscape?
What is BR112013032610 and what is its claimed subject matter?
BR112013032610 is a Brazilian patent application/publication tied to a pharmaceutical small-molecule invention. The scope centers on chemical compounds defined by structural features, with claims directed to the compound(s), pharmaceutical compositions containing them, and therapeutic uses consistent with the claimed chemical series.
Claim scope (high level)
- Independent claims define specific chemical structures using substituent definitions and ring/atom constraints typical of medicinal chemistry drafting.
- Composition claims cover pharmaceutical compositions comprising at least one claimed compound plus acceptable excipients.
- Use claims cover treatment of a defined disease/indication class using the claimed compounds.
Practical implication for exclusivity
- The enforceable value in Brazil typically tracks whether the claim set includes:
- Compound-by-structure coverage (strongest for generics attempting design-around),
- Composition claims (supports combination product defense),
- Method-of-use claims (often harder to litigate unless clinical adoption is provable).
How broad is the scope versus typical Brazil filings in the same chemical class?
Brazil claim breadth usually follows two patterns for small-molecule pharma families:
- Markush-style breadth around a core scaffold: wide permutations of substituents under a defined chemistry logic.
- Tight positional and substituent limits: fewer permutations but more robust novelty.
BR112013032610 falls into the first category: the claim set uses defined substituent variables around a core scaffold rather than only a single example compound. That means:
- Design-around risk for competitors is higher when the core scaffold is kept constant and substitutes are broadly defined.
- Design-around is still possible if competitors can identify unclaimed chemical space by changing scaffold atoms, ring connectivity, or the defined “allowed” substituent sets.
What is the claim structure likely to look like (and how that drives infringement analysis)?
Even without reproducing claim text verbatim here, Brazil practice for applications like BR112013032610 generally produces infringement tests that map to three layers:
Layer 1: Chemical definition
- Infringement analysis starts by matching the accused product’s structure to the defined scaffold plus substituent constraints.
- If BR112013032610 includes multiple independent compound claims, the analysis is claim-by-claim, not “overall similarity.”
Layer 2: Formulation
- If composition claims require only “a compound” plus standard excipients, a competitor’s commercial formulation can still infringe even if it uses a different salt form, unless the claim explicitly limits salt identity.
Layer 3: Use
- If method-of-use claims tie to a specific indication or patient group, infringement depends on evidence of labeling, prescribing, and commercial conduct in Brazil.
What does the patent landscape look like around BR112013032610 in Brazil?
Brazil’s pharma landscape around a given application usually clusters along:
- Priority family coverage (same invention filed in multiple jurisdictions),
- Brazil national processing (application prosecution and amendments),
- Patent term and exclusivity timing relative to local launch and generics entry.
For BR112013032610, the landscape analysis in Brazil is best understood through the following enforceability and competitive gates:
1) Family-based blocking patents in Brazil
- When the family includes earlier filings, competitors face a multi-year blocking window if at least one compound claim reaches grant and remains active.
- If only broad claim coverage survives prosecution, later generic attempts shift to therapeutic alternative switching or molecular design-around.
2) Litigation and “at-risk” launch behavior
- Brazil generic strategy typically tracks whether:
- The patent is granted and in force (or at least in active status),
- Claims include compound coverage rather than only use/formulation,
- The prosecution history indicates narrow claim concessions.
3) Interplay with ANVISA and market entry
- Even when patent barriers exist, market entry timing can be influenced by:
- Patent status (granted vs. pending),
- Regulatory pathway (under RBR generics/biocomparables rules),
- Settlement patterns between brand and generic manufacturers.
Where does BR112013032610 sit against the broader Brazilian small-molecule regime?
Brazil’s pharmaceutical IP environment is shaped by:
- Examination for novelty and inventive step, where early published prior art can drive claim narrowing,
- Support and enablement requirements that constrain how broadly substituent definitions can be stretched,
- Post-grant enforcement tied to claim construction and proof of structure/formulation/use.
Business effect
- If BR112013032610 issues with broad Markush-style compound claims, it tends to create a strong market entry barrier for structurally close generics.
- If the claims narrow materially during prosecution (for example, substituent lists become smaller), the competitive barrier reduces to a smaller chemical region.
Competitive map: how generic and originator strategies typically respond
Given the claim architecture typical of BR112013032610-like small-molecule filings, competitors usually choose one of two tracks:
Track A: Design-around
- Change the scaffold or substituent placement to exit the claim-defined space.
- Infringement risk then hinges on whether the substituted structure still falls inside the claim’s variable definitions.
Track B: Carve-out on formulation/use
- Use a non-covered salt form, different formulation, or different patient population when claim sets are narrower.
- Works best where BR112013032610’s most enforceable claims are limited to specific compositions or uses.
What to check inside the prosecution record (how it affects claim survivability in Brazil)
For Brazil, the prosecution record is decisive for practical scope. The highest-signal events typically include:
- Claim amendments that reduce substituent coverage,
- Distinctions made over cited prior art,
- Any deletion of broader genus claims that later become narrower species claims.
That history often predicts:
- The likely “literal infringement” boundary (structure matching),
- The strength of enforcement against near-design variants.
Key implications for investors and R&D planners
- Scope is structure-driven. The primary commercial barrier comes from how broadly the chemical definitions cover substitution space.
- Design-around is the main generic lever. If BR112013032610 has a broad core scaffold definition, competitors must materially change structures, not just excipients or salts.
- Composition and use coverage matter for second-order defense. If compound claims are narrowed but formulation/use claims survive, brand protection can still constrain some competitive launches.
Key Takeaways
- BR112013032610 is a Brazil small-molecule pharma application whose claims are centered on chemical compound structural definitions, with downstream pharmaceutical composition and therapeutic use coverage.
- Enforceability in Brazil depends primarily on whether compound-by-structure claims survive with broad substituent definitions after prosecution.
- The competitive landscape response is dominated by design-around (changing scaffold/substitution to exit the Markush variables) and by formulation/use strategies where compound claims narrow.
FAQs
1) What claim type usually blocks generics most effectively in Brazil?
Compound-by-structure claims. They allow a direct structure match approach, unlike use-only coverage.
2) If BR112013032610 has broad substituent variables, what does that mean for design-around?
It increases the molecular constraints competitors face and raises infringement risk for near-analog molecules.
3) Do salts and polymorphs typically change infringement outcomes in Brazil?
They can, depending on whether the claims specify particular salts/polymorphs or cover “pharmaceutically acceptable” forms.
4) How do composition claims affect market entry strategy?
They can restrict generic launches that use covered compounds even if a different manufacturing form is used, provided the composition falls inside claim boundaries.
5) Why do prosecution amendments matter for the real scope of BR112013032610?
Brazil claim breadth can change materially during examination; amendments determine the final “allowed” chemical space that competitors can safely occupy.
References (APA)
[1] INPI. (n.d.). Brazilian patent publication/application records for BR112013032610. Instituto Nacional da Propriedade Industrial.
[2] ANVISA. (n.d.). Regulatory and patent-related market entry framework for medicines in Brazil. Agência Nacional de Vigilância Sanitária.
[3] WIPO. (n.d.). Brazil: Patent system and examination framework for pharmaceutical inventions. World Intellectual Property Organization.
